vir-3434
mAbexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started May 26, 2020 (NCT04423393)
Timeline
Indications
Mechanism of action
- Hepatitis B virusImmunity, passive
Hepatitis B virus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314621 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07142811 | Phase 2 | Aug 5, 2025 | Vir Biotechnology, Inc. |
| NCT07128550 | Phase 3 | Jul 30, 2025 | Vir Biotechnology, Inc. |
| NCT06903338 | Phase 3 | Mar 12, 2025 | Vir Biotechnology, Inc. |
| NCT06216470 | Phase 2 | Mar 13, 2024 | University of Toronto |
| NCT05612581 | Phase 1/Phase 2 (Phase 2) | Nov 9, 2022 | Vir Biotechnology, Inc. |
| NCT05484206 | Phase 1 | Sep 21, 2022 | Vir Biotechnology, Inc. |
| NCT05461170 | Phase 2 | Sep 17, 2022 | Vir Biotechnology, Inc. |
| NCT04856085 | Phase 2 | Jul 11, 2021 | Vir Biotechnology, Inc. |
| NCT04423393 | Phase 1 | May 26, 2020 | Vir Biotechnology, Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vir Biotechnology, Inc. | For profit | 8 | 8 | 3 | 2020 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2024 |
2 organizations
Page 1 / 1